Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Declines By 20.6%

TScan Therapeutics, Inc. (NASDAQ:TCRX) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 2,000,000 shares, a decline of 20.6% from the December 31st total of 2,520,000 shares. Currently, 4.6% of the shares of the stock are sold short. Based on an average daily volume of 403,800 shares, the days-to-cover ratio is currently 5.0 days.

TScan Therapeutics Price Performance

NASDAQ TCRX traded down $0.01 during trading hours on Friday, reaching $2.57. The company had a trading volume of 218,891 shares, compared to its average volume of 275,131. TScan Therapeutics has a 1-year low of $2.31 and a 1-year high of $9.69. The stock has a 50-day moving average of $3.20 and a 200 day moving average of $4.77. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The company had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.86 million. Analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Trading of TScan Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of TScan Therapeutics in the fourth quarter valued at approximately $32,000. Heck Capital Advisors LLC acquired a new stake in shares of TScan Therapeutics in the fourth quarter valued at $61,000. SG Americas Securities LLC boosted its holdings in TScan Therapeutics by 31.2% in the fourth quarter. SG Americas Securities LLC now owns 20,415 shares of the company’s stock valued at $62,000 after purchasing an additional 4,852 shares during the period. Dimensional Fund Advisors LP acquired a new position in TScan Therapeutics during the 2nd quarter worth $70,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in TScan Therapeutics during the 2nd quarter worth about $90,000. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TCRX has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a research note on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a report on Wednesday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $7.00 price target on shares of TScan Therapeutics in a report on Monday, December 23rd.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.